This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Celgene Corporation. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Preethi Janardhanan: Innovator in Cancer Treatment
Introduction
Preethi Janardhanan is a notable inventor based in San Diego, California. He has made significant contributions to the field of medicine, particularly in the treatment of chronic lymphocytic leukemia. His innovative approach has the potential to impact many lives.
Latest Patents
Janardhanan holds a patent for "Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione." This patent outlines methods for using this compound, either alone or in combination with obinutuzumab, to treat, prevent, or manage chronic lymphocytic leukemia and small lymphocytic lymphoma.
Career Highlights
Currently, Janardhanan is associated with Celgene Corporation, where he continues to work on innovative solutions in cancer treatment. His research and development efforts are focused on improving therapeutic options for patients suffering from chronic lymphocytic leukemia.
Collaborations
Janardhanan collaborates with esteemed colleagues, including Shailaja Kasibhatla and Antonia Lopez-Girona, who contribute to his research endeavors. Their combined expertise enhances the potential for groundbreaking advancements in cancer therapies.
Conclusion
Preethi Janardhanan's work exemplifies the spirit of innovation in the medical field. His contributions to cancer treatment through his patented methods highlight the importance of research and collaboration in advancing healthcare solutions.